GlassScriptPhysician profile
Stephen L Raben
NPI 1649228990
$5,027.05
in general payments reported to CMS, 2019-2025
36 companies · $114 in 2025
The $114 reported for 2025 was less than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,013 · 2020: $775 · 2021: $1,211 · 2022: $877 · 2023: $821 · 2024: $215 · 2025: $114.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,151.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,150.85 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $842.37 | 2021-2023 | |
| Astrazeneca Pharmaceuticals LP | $471.47 | 2019-2023 | Farxiga |
| Lilly USA, LLC | $355.18 | 2019-2025 | Mounjaro, Zepbound |
| Pfizer INC. | $320.93 | 2019-2024 | |
| Kowa Pharmaceuticals America, INC. | $272.33 | 2019-2023 | Livalo, Seglentis |
| Novo Nordisk INC | $254.13 | 2019-2025 | Rybelsus, Ozempic |
| Allergan, INC. | $240.57 | 2020 | |
| E.R. Squibb & Sons, L.L.C. | $212.97 | 2019-2023 | Eliquis |
| Takeda Pharmaceuticals U.S.A., INC. | $198.38 | 2019-2022 | |
| Sanofi-Aventis U.S. LLC | $184.26 | 2019-2023 | |
| Astellas Pharma US INC | $156.19 | 2019-2024 | Veozah, Myrbetriq |
| Merck Sharp & Dohme LLC | $121.61 | 2019-2024 | Gardasil, Gardasil 9, Capvaxive |
| Boehringer Ingelheim Pharmaceuticals, INC. | $109.99 | 2019-2023 | Tradjenta, Jardiance, Synjardy |
| Amgen INC. | $106.17 | 2021-2025 | Repatha, Repatha |
| Novartis Pharmaceuticals Corporation | $102.63 | 2019-2024 |
Show all 36 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Stephen Raben listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.